Medtronic plc stock (IE00BTN1Y115): shares trade near 52-week low as valuation comes into focus

Medtronic shares on the New York Stock Exchange traded in the mid-USD 70s on 05/29/2026, keeping the medical device group close to a newly marked 52-week low as investors reassessed valuation and income characteristics of the stock in the United States market.

According to Business Insider price data, Medtronic opened at USD 75.61 on 05/29/2026 on the NYSE under the ticker MDT, compared with a previous close around USD 75.56, while the 12-month trading range currently runs from roughly USD 74.40 to about USD 106.33 based on recent quote summaries as of 05/29/2026.

The move leaves the Dublin-headquartered and U.S.-listed medtech blue chip trading near the bottom of that band, even as consensus data compiled by MarketBeat points to an average analyst price target of about USD 106.45 and a "Moderate Buy" consensus rating as of 05/29/2026.

This positioning in the lower part of the range means Medtronic’s equity story for U.S. investors is currently framed less by short-term price momentum and more by the interaction of earnings power, balance sheet strength and cash returns through dividends at this stage of the cycle.

In the primary U.S. market, Medtronic’s share price around the mid-USD 70s implies that the stock is trading at a discount to the average broker target compiled by MarketBeat, which sits in the low triple digits in USD, highlighting a notable gap between market pricing and analyst valuation models as of late May 2026.

While Germany is only a secondary venue for the stock, Medtronic also changes hands in euro on platforms such as Tradegate, allowing European retail investors to follow the U.S. price performance through local trading infrastructure alongside the core NYSE listing.

Beyond daily price fluctuations, recent institutional filings underline ongoing interest from large investors: National Pension Service disclosed the purchase of 28,269 Medtronic shares, while FLPutnam Investment Management reported holdings of 20,537 shares valued at about USD 1.97 million for the fourth quarter in a filing referenced by MarketBeat on 05/29/2026.

These holdings updates do not alter the strategic picture but do show that long-term institutions continue to adjust positions in the stock at current price levels, adding another datapoint to the debate about whether the present valuation adequately reflects Medtronic’s earnings profile and dividend stream.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

Medtronic plc: core business model

Medtronic focuses on developing and supplying advanced medical devices across cardiovascular, neuroscience and surgical therapies, with sales largely generated by hospitals and care providers that adopt its implantable systems and related technologies.

Valuation metrics and multiples for Medtronic plc

With Medtronic trading near USD 75 in late May 2026 and consensus broker targets gathered by MarketBeat around USD 106.45, the stock’s market price in the United States stands well below aggregated sell-side valuation estimates, underlining a substantial implied upside in those models as of 05/29/2026.

While precise real-time valuation ratios require up-to-the-minute earnings inputs, recent data from quote services indicate that, at these levels, Medtronic is typically valued on a forward price-to-earnings multiple below its 12-month high area, while still reflecting its status as a large-cap medical device group with a track record of paying regular dividends that many U.S. income-oriented investors monitor as part of the overall total-return profile.

Conclusion

Medtronic’s U.S.-listed shares are currently trading close to a fresh 12-month low, even as institutional investors continue to adjust positions and broker consensus targets remain materially above the prevailing market price.

For market participants following the stock on the NYSE or via German trading venues, the present level puts the focus squarely on how valuation multiples and the dividend stream stack up against the company’s earnings outlook and broader medtech sector dynamics over the coming quarters.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.